Browse the evidence

Persistent medication coverage was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 3.36).

Ensuring patients maintain their medication regimen may significantly improve weight loss outcomes.

In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.

Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.

In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.

Maridebart cafraglutide may also be effective for weight loss in individuals with obesity and type 2 diabetes.

Tirzepatide would avert 45,609 obesity cases per 100,000 individuals over a lifetime.

Tirzepatide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide would avert 32,087 obesity cases per 100,000 individuals over a lifetime.

Semaglutide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Glycemic control and hyperinsulinemia are improved by low-carbohydrate diets.

Low-carbohydrate diets may be recommended to improve glycemic control in patients.

Late bedtime was associated with general obesity (AOR, 1.20; 95% CI, 1.12-1.29) and abdominal obesity (AOR, 1.20; 95% CI, 1.12-1.28).

Encouraging earlier bedtimes may help reduce obesity risk.

Short nocturnal sleep of less than 6 hours was associated with general obesity (e.g., <5 hours: AOR, 1.27; 95% CI, 1.13-1.43).

Limiting sleep duration to at least 6 hours may help mitigate obesity risk.

Using tirzepatide resulted in a weight loss of 17.8% compared with 12.4% for semaglutide.

Tirzepatide may be more effective for weight loss in patients with type 2 diabetes.

Multiple risk factors should be targeted simultaneously in T2DM patients to reduce CV events.

A comprehensive approach addressing multiple risk factors is essential for effective cardiovascular disease prevention in T2DM patients.

Tirzepatide treatment significantly reduced the 10-year predicted risk of developing type 2 diabetes compared with placebo in participants with obesity or overweight.

Practitioners can consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Excess body weight is a significant risk factor for breast cancer and increases the risk of therapy-related morbidity, recurrence, and breast cancer-related mortality.

Healthcare providers should prioritize weight management in breast cancer patients and survivors.

An active perioperative GLP-1 RA prescription in patients with diabetes was associated with a significantly reduced risk of 30-day readmission (RR: 0.883; P = 0.028).

Practitioners may consider GLP-1 RA prescriptions to reduce readmission rates in diabetic surgical patients.

The MR group experienced a significantly higher increase in lean mass, strength, and power than the PR group after 6 weeks of resistance training.

Incorporating high-protein dairy milk post-exercise and pre-sleep may enhance muscle gains and strength in young males undergoing resistance training.

Serum levels of IGF-1, growth hormone, testosterone, and follistatin increased, while cortisol and myostatin decreased in the MR group compared to the PR group.

Monitoring hormonal responses may provide insights into the effectiveness of dietary interventions in resistance training.

Strategic ingestion of high-protein dairy milk augmented lean mass, strength, power, and altered serum concentrations of skeletal muscle regulatory markers.

Implementing high-protein dairy milk in post-exercise and pre-sleep nutrition can enhance training outcomes.

The percentage of weight loss as fat-free mass (%FFML) using GLP-1RA-based agents was between 20% and 40%.

Practitioners can expect that GLP-1RA treatments may lead to significant fat-free mass loss.

AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks.

Practitioners can consider AOMs as effective long-term options for weight management.

Medication options are available to treat obesity, which can help reduce appetite and/or reduce caloric intake.

Practitioners can consider pharmacological treatments to assist patients in managing obesity.

GLP-1 receptor agonists have been successfully used in the treatment of obesity and type 2 diabetes.

GLP-1 receptor agonists can be considered as a treatment option for patients with obesity and T2DM.

Postexercise whole egg ingestion increases knee extension and handgrip strength, testosterone, and reduces body fat percentage compared with postexercise egg white ingestion.

Practitioners may consider recommending whole egg consumption post-exercise for improved strength and body composition.

There was a significant group × time interaction for body fat percentage, serum testosterone, knee extension, and handgrip strength with greater improvements observed in the whole egg group.

The results suggest that whole egg consumption may be more beneficial for strength and body composition improvements during resistance training.

Tirzepatide has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.

Tirzepatide may be a more effective option for managing HbA1c and body weight in patients compared to existing therapies.

Semaglutide therapy resulted in a 62.9% resolution of MASH without worsening of fibrosis compared to 34.3% in placebo (p <0.001).

Clinicians can consider semaglutide as an effective treatment option for MASH with moderate-to-advanced fibrosis.